Opendata, web and dolomites

Fingers4Cure

Zinc finger gene therapy in the brain for treating Huntington's disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Fingers4Cure project word cloud

Explore the words cloud of the Fingers4Cure project. It provides you a very rough idea of what is the project "Fingers4Cure" about.

usa    viral    property    finger    et    expanded    normal    brain    parallel    curative    protect    single    cure    mouse    proteins    national    dna    industry    function    engineered    35    inherited    basis    garriga    e3145    vectors    2012    repression    reduce    levels    huntingtin    mutant    al    zinc    moves    licenses    phases    intellectual    defective    earlier    r6    45    mice    engaging    proprietary    natl    bind    sci    artificially    arise    patent    canut    proc    regional    zfps    suffering    expression    disease    repressors    ipr    isalan    demonstrating    proof    published    critical    huntington    grant    unrelated    e3136    symptoms    sequences    synthesis    synthetic    carers    coding    diagnosis    data    age    htt    patients    humans    acad    109    accomplished    hd    improvements    market    maintaining    lethal    gene    start    neurodegenerative    muscle    toxic    protein    intervention    reducing    disorder    binding    generally    15    represses    efficient    therapy    carry    occurring    devastating    clinic    death   

Project "Fingers4Cure" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙995 €
 EC max contribution 149˙995 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 149˙995.00

Map

 Project objective

Huntington’s disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. Patients develop a devastating loss of muscle control and brain function, with symptoms typically developing at 35 - 45 years of age, although they can start much earlier. Suffering is high for both patients and carers, with death generally occurring within 10 - 15 years of diagnosis. We are working on a novel, curative gene therapy approach based on reducing the levels of the HTT disease gene products, while maintaining the levels of the normal protein. It is based on the delivery of proprietary zinc finger proteins (ZFPs) to the brain. Efficient delivery is accomplished through the use of viral vectors that carry the sequences coding for our ZFPs. Such ZFPs are artificially engineered proteins that specifically bind the defective expanded HTT DNA sequences (but not the normal HTT sequences or other, unrelated sequences). Binding represses the synthesis of the toxic gene products. We have published data demonstrating efficient mutant HTT repression in mouse (Garriga-Canut, M., et al. & Isalan M. Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-E3145, 2012). We now need to improve the viral vectors for the long term expression of our ZFPs in the mouse brain, as the basis for a single-intervention, long-term therapy in humans (technical improvements). In parallel, we need to maintain the patent applications that protect the technology through various national and regional phases, and protect new developments that may arise (intellectual property), while engaging the necessary IPR and market studies/activities that help us find an industry partner that licenses our technology and moves it forward into the clinic (exploitation). This proof of concept grant is critical in all three aspects.

 Publications

year authors and title journal last update
List of publications.
2015 Michal Mielcarek, Mark Isalan
A shared mechanism of muscle wasting in cancer and Huntington’s disease
published pages: , ISSN: 2001-1326, DOI: 10.1186/s40169-015-0076-z
Clinical and Translational Medicine 4/1 2019-07-23
2016 Carmen Agustín-Pavón, Michal Mielcarek, Mireia Garriga-Canut, Mark Isalan
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice
published pages: , ISSN: 1750-1326, DOI: 10.1186/s13024-016-0128-x
Molecular Neurodegeneration 11/1 2019-07-23
2015 Michal Mielcarek
Huntington\'s disease is a multi-system disorder
published pages: e1058464, ISSN: 2167-5511, DOI: 10.1080/21675511.2015.1058464
Rare Diseases 3/1 2019-07-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FINGERS4CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FINGERS4CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CerQuS (2019)

Certified Quantum Security

Read More  

UEMHP (2019)

Unravelling Earth’s magnetic history and processes

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More